Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.
Lilly’s Curevo deal turns AAHI’s adjuvant science into a late-stage vaccine opportunity
Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.
Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system
Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.
FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight
RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.
Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.
Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?
Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.
Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.
Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.